Compare Stocks

American Strategic Income Portfolio Inc. (ASP) invests in mortgage-related assets that directly or indirectly represent a participation in or are secured by and payable from mortgage loans. The Fund may also invest in the United States Government securities, corporate debt securities, preferred stock issued by real estate investment trusts, and mortgage servicing rights. In addition, the Fund may borrow using reverse repurchase agreements and credit facilities. The Fund's primary objective is to achieve high levels of current income. Its secondary objective is to seek capital appreciation. The Barclays Capital Mutual Fund Government/Mortgage Index, ASP's benchmark, consists of all the United States Government agency and Treasury securities and agency mortgage-backed securities. The Fund's investment advisor is U.S. Bancorp Asset Management, Inc. ASP's sub-advisors include Nuveen Asset Management, LLC and Nuveen Fund Advisors, Inc.

ECMOHO Limited, an investment holding company, operates as an integrated solution provider in the health and wellness market. The company offers health supplements and food, mother and child care products, personal care products, and household healthcare equipment and cleaning products. It sells its products through flagship stores of its brand partners, self-operated branded stores on third-party e-commerce platforms; and other small and medium-sized online and offline retailers. The company is also involved in the provision of bonded area warehousing; online store operating services; and promotion and marketing services to its brand partners and other brand customers. It serves consumers and retailers. The company was founded in 2011 and is headquartered in Shanghai, the People's Republic of China.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.